Department of Pharmacology 3FM CU
https://www.lf3.cuni.cz/3LF-400.html
Topic title
Pharmacokinetics
Pharmacovigilance in oncology
Pharmacokinetics - Use of software MW-Pharm in therapeutic monitoring of levels of antidepressant or depot antipsychotic drugs
Pharmacovigilance in oncology - Incidence of serious or unexpected adverse events during treatment with capecitabine or 5-fluorouracil in patients screened for the presence of complete dihydropyrimidine dehydrogenase deficiency
P. Potměšil and R. Straková. Drug induced liver injury after switching from tamoxifen to anastrozole in a patient after breast cancer being treated for hypertension and diabetes. Therapeutic Advances in Chronic Disease 2020; 11: 1-11.
P. Potměšil. What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice. Therapeutic Advances in Psychopharmacology 2019; 9: 1-11.
M. Kopeček and P. Potměšil. How long does the pharmacokinetic interaction between carbamazepine and quetiapine last after carbamazepine withdrawal? Neuro Endocrinol Lett. 2017; 38: 475-478.
2020-2026: TheraLymph –Gene Therapy to restore lymphatic flow lymphedema, H2020 SC1-BHC-07-2019, Project # 874708
2021-2024: Novel approaches to enhance insulin-sensitizing effects of exercise: targeting PAHSA metabolism ETAPA; Czech Health Research Council project NU21-01-00469
2019 - 2022: Pancreatic cancer: metabolic derangements assiocated with insulin resistence (PAMIR), Czech Health Research Council project NV19-01-00101, Co-PI: Lenka Rossmeislova
Third Faculty of Medicine
Charles University
Ruská 87, 100 00 Prague 10
Czech Republic
Phone.: +420 267 102 111
Data Box ID: piyj9b4
ID No.: 00216208, VAT No.: CZ00216208